Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-

British Journal of Nutrition

Volumn 103, Issue 5, 2010, Pages 652-662

  Takechi, Ryusuke ^a,b,c   Galloway, Susan ^a,b,c   Pallebage Gamarallage, Menuka M S ^a,b,c   Wellington, Cheryl L ^d   Johnsen, Russell D ^e,f   Dhaliwal, Satvinder S ^a,b,c   Mamo, John C L ^a,b,c  

^a CURTIN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c Australian Technology Network   (Australia)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f Australian Neuromuscular Research Institute   (Australia)

Author keywords

Alzheimer's disease; Amyloid ; Blood brain barrier; SFA; TAG rich lipoproteins

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN B; IMMUNOGLOBULIN G; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; PRESENILIN 1; PROTEIN S100B; SATURATED FATTY ACID; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; FATTY ACID; MEMBRANE PROTEIN; OCCLUDIN; UNSATURATED FATTY ACID;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN REGION; BRAIN STEM; CONTROLLED STUDY; FAT INTAKE; FEMALE; HIPPOCAMPUS; IMMUNOREACTIVITY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK ASSESSMENT; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BLOOD; BRAIN; C57BL MOUSE; DISEASE MODEL; METABOLISM; METHODOLOGY; MICROSCOPY; RISK FACTOR;

MURINAE; MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; BRAIN; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY ACIDS; FATTY ACIDS, UNSATURATED; FEMALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICROSCOPY; PRESENILIN-1; RISK FACTORS; TISSUE DISTRIBUTION;

EID: 77949523096     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114509992194     Document Type: Article

References (60)

1. Pasinetti GM & Eberstein JA (2008) Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J Neuro-chem 106, 1503-1514.
2. Kalmijn S (2000) Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging 4, 202-207.
3. Petot GJ & Friedland RP (2004) Lipids, diet and Alzheimer's disease: an extended summary. J Neurol Sci 226, 31-33.
4. Sparks DL, Scheff SW, Hunsaker JC III, et al. (1994) Induction of Alzheimer-like b-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94.
5. Refolo LM, Malester B, LaFrancois J, et al. (2000) Hyper-cholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
6. Ellis RJ, Olichney JM, Thal LJ, et al. (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46, 1592-1596.
7. Kalaria RN (1992) The blood-brain barrier and cerebral micro-circulation in Alzheimer disease. Cerebrovasc Brain Metab Rev 4, 226-260.
8. Wisniewski HM, Vorbrodt AW & Wegiel J (1997) Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann NY Acad Sci 826, 161-172.
9. Cullern KM (1997) Perivascular astrocytes within Alzheimer's disease plaques. Neuroreport 8, 1961-1966.
10. Itagaki S, McGeer PL, Akiyama H, et al. (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24, 173-182.
11. Hachinski V & Munoz DG (1997) Cerebrovascular pathology in Alzheimer's disease: cause, effect or epiphenomenon? Ann N Y Acad Sci 826, 1-6.
12. Joachim CL, Duffy LK, Morris JH, et al. (1988) Protein chemical and immunocytochemical studies of meningovascular b-amyloid protein in Alzheimer's disease and normal aging. Brain Res 474, 100-111.
13. Deane R, Sagare A, Hamm K, et al. (2005) IgG-assisted age-dependent clearance of Alzheimer's amyloid b peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25, 11495-11503.
14. Mackic JB, Bading J, Ghiso J, et al. (2002) Circulating amyloid-b peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol 38, 303-313.
15. Crossgrove JS, Li GJ & Zheng W (2005) The choroid plexus removes b-amyloid from brain cerebrospinal fluid. Exp Biol Med 230, 771-776.
16. Donahue JE, Flaherty SL, Johanson CE, et al. (2006) RAGE, LRP-1, and amyloid-b protein in Alzheimer's disease. Acta Neuropathol 112, 405-415.
17. Galloway S, Jian L, Johnsen R, et al. (2007) b-Amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. J Nutr Biochem 18, 279-284.
18. Takechi R, Galloway S, Pallebage-Gamarallage MMS, et al. (2008) Chylomicron amyloid-b in the aetiology of Alzheimer's disease. Atheroscler Supp 9, 19-25.
19. Koudinov AR & Koudinova NV (1997) Alzheimer's soluble amyloid b protein is secreted by HepG2 cells as an apo-lipoprotein. Cell Biol Int 21, 265-271.
20. James AP, Pal S, Gennat HC, et al. (2003) The incorporation and metabolism of amyloid-b into chylomicron-like lipid emulsions. J Alzeimers Dis 5, 179-188.
21. Mamo JC, Jian L, James AP, et al. (2008) Plasma lipoprotein b-amyloid in subjects with Alzheimer's disease or mild cognitive impairment. Ann Clin Biochem 45, 395-403.
22. Smith D, Watts GF, Dane-Stewart C, et al. (1999) Post-prandial chylomicron response can be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 29, 204-209.
23. Boyt AA, Taddei TK, Hallmayer J, et al. (2000) The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein. Neuroscience 95, 727-734.
24. LaRue B, Hogg E, Sagare A, et al. (2004) Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-b peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods 138, 233-242.
25. Burgess BL, McIsaac SA, Naus KE, et al. (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A b in plasma. Neurobiol Dis 24, 114-127.
26. Arendash GW, Su GC, Crawford FC, et al. (1999) Intravascular b-amyloid infusion increases blood pressure: implications for a vasoactive role of b-amyloid in the pathogenesis of Alzheimer's disease. Neurosci Lett 268, 17-20.
27. 1-40 across the murine blood-brain barrier. Life Sci 55, 1643-1650.
28. Thomas T, McLendon C, Sutton ET, et al. (1997) Cerebro-vascualr endothelial dysfunction mediated by b-amyloid. Neuroreport 8, 1387-1391.
29. Natah SS, Mouihate A, Pittman QJ, et al. (2005) Disruption of the blood-brain barrier during TNBS colitis. Neurogastro-enterol Motil 17, 433-446.
30. Kay AD, Day SP, Nicoll JA, et al. (2003) Remodelling of cere-brospinal fluid lipoproteins after subarachnoid hemorrhage. Atherosclerosis 170, 141-146.
31. Takechi R, Galloway S, Pallebage-Gamarallage MM, et al. (2008) Three-dimensional immunofluorescent double labelling using polyclonal antibodies derived from the same species: enterocytic colocalization of chylomicrons with Golgi apparatus. Histochem Cell Biol 129, 779-784.
32. Kleindienst A, Hesse F, Bullock MR, et al. (2007) The neuro-trophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog Brain Res 161, 317-325.
33. Yang Q, Hou X, Hamberger A, et al. (1995) S-100 b immunor-eactivity in neurons of the rat peripheral sensory ganglia. Neuroreport 6, 2005-2009.
34. Kawai M, Kalaria RN, Harik SI, et al. (1990) The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol 137, 1435-1446.
35. Yanagisawa K, McLaurin J, Michikawa M, et al. (1997) Amyloid b-protein (A b) associated with lipid molecules: immunoreactivity distinct from that of soluble A b. FEBS Lett 420, 43-46.
36. James AP & Mamo JC (2005) The immunodetection of lipoprotein-bound amyloid-b is attenuated because of the presence of lipids. Ann Clin Biochem 42, 70-72.
37. Morgan NG (2009) Fatty acids and b-cell toxicity. Curr Opin Clin Nutr Metab Care 12, 117-122.
38. Carpentier AC (2008) Postprandial fatty acid metabolism in the development of lipotoxicity and type 2 diabetes. Diabetes Metab 34, 97-107.
39. Cnop M, Igoillo-Esteve M, Chunha DA, et al. (2008) An update on lipotoxic endoplasmic reticulum stress in pancreatic b-cells. Biochem Soc Trans 36, 909-915.
40. Solfrizzi V, Frisardi V, Capurso C, et al. (2009) Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms. Ageing Res Rev (epublication ahead of print version 28 July 2009).
41. Van oostrom AJ, Alipour A, Plokker TW, et al. (2007) The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 190, 167-173.
42. Patil S, Balu D, Melrose J, et al. (2008) Brain region-specificity of palmitic acid-induced abnormalities associated with Alzheimer's disease. BMC Res Notes 1, 20.
43. Diakogiannaki E & Morgan NG (2008) Differential regulation of the ER stress response by long-chain fatty acids in the pancreatic b-cell. Biochem Soc Trans 36, 959-962.
44. Unger RH (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44, 863-870.
45. Deane R, Sagare A, Hamm K, et al. (2008) ApoE isoform-specific disruption of amyloid b peptide clearance from mouse brain. J Clin Invest 118, 4002-4013.
46. Deane R, Bell RD, Sagare A, et al. (2009) Clearance of amyloid-b peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8, 16-30.
47. Namba Y, Tsuchiya H & Ikeda K (1992) Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer's disease. Neurosci Lett 134, 264-266.
48. Cole GM & Ard MD (2000) Influence of lipoproteins on microglial degradation of Alzheimer's amyloid b-protein. Microsc Res Tech 50, 316-324.
49. Clifford PM, Zarrabi S, Siu G, et al. (2007) Ab peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142, 223-236.
50. Takechi R, Galloway S, Pallebage-Gamarallage M, et al. (2009) Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. Histochem Cell Biol 131, 661-666.
51. Kreuter J, Hekmatara T, Dreis S, et al. (2007) Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release 118, 54-58.
52. Caramelli P, Nitrini R, Maranhao R, et al. (1999) Increased apolipoprotein B serum concentration in Alzheimer's disease. Acta Neurol Scand 100, 61-63.
53. Mamo JC, Proctor SD& Smith D (1998) Retentionof chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis 141, S63-S69.
54. Elsegood CL, Pal S, Roach PD, et al. (2001) Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins. Clin Sci 101, 111-119.
55. Profenno LA, Porsteinsson AP & Faraone SV (2009) Meta-analysis of Alzheimer's disease risk with obesity, diabetes and related disorders. Biol Psychiatry (epublication ahead of print version 7 April 2009).
56. Mamo JC, Watts GF, Barrett PH, et al. (2001) Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol Endocrinol Metab 281, E626-E632.
57. Nelson TJ & Alkon DL (2007) Protection against b-amyloid-induced apoptosis by peptides interacting with b-amyloid. J Biol Chem 282, 31238-31249.
58. Laitinen MH, Ngandu T, Rovio S, et al. (2006) Fat intake at midlife and risk of dementia and Alzheimer's disease: a population based study. Dement Geriatr Cogn Disord 22, 99-107.
59. Schaefer EJ, Bongard V, Beiser AS, et al. (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63, 1545-1550.
60. Oksman M, Iivonen H, Hogyes E, et al. (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on b-amyloid accumulation in APP/PS1 trangenic mice. Neurobiol Dis 23, 563-572.